Janux Therapeutics (NASDAQ: JANX - Get Free Report) and Roivant Sciences (NASDAQ: ROIV - Get Free Re

On Thursday, Roivant Sciences (NASDAQ:ROIV) discussed first-quarter financial results during its ear

What happened Roivant Sciences Ltd. (NASDAQ: ROIV) said Eric Venker, its president and Immunovant CE

Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an ann

Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant share

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CL

Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN ra

Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rati

TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the

Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises th

HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering

Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's

U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, a

Jefferies analyst Dennis Ding maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the

U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris,

Roivant announced positive Phase 2 trial results for mosliciguat, demonstrating improved walk distan

Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market s

"PH-ILD remains one of the most challenging forms of pulmonary hypertension to treat, given the

FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raise

Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises th

HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analy

HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myosi

U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation f

US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe&#39

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

Last week's top large-cap gainers surged on strong earnings beats and upbeat guidance (LITE, XPO

The software-driven sell-off paused for a breather on Friday after eight straight sessions that had

U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.

Sun Pharma is evaluating a potential $10 billion acquisition of Organon, a move that could become In

Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff con

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its